Navigation Links
Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
Date:3/19/2012

SAN DIEGO, March 19, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQB: ONVO) ("Organovo") today announced the final closing of an oversubscribed $15.2 million private placement. At the final closing, the Company raised gross proceeds of $6.9 million through the sale of 6.9 million Units, at a price of $1.00 per Unit, to accredited investors. Post-closing Organovo has approximately 43.7 million shares of common stock issued and outstanding.

As previously announced, the Company raised $6.5 million in gross proceeds on February 8, 2012, in the first closing of the private placement, and $1.8 million in gross proceeds on February 29, 2012, in the second closing. During the entire private placement, the Company raised total gross proceeds of $15.2 million and total net proceeds of $12.8 million. Spencer Trask Ventures, Inc. served as placement agent.

"The response to our private financing has been tremendous, and we're grateful for investors' enthusiasm for our progress to date and our strong potential," stated Keith Murphy, chief executive officer of Organovo. "The financing allows Organovo to continue to pursue our goals in commercializing 3D bioprinting technologies and products in biological and medical research."

As announced on February 14, 2012, after having completed a merger in association with the first closing of the private placement, Organovo will continue the business of Organovo, Inc., headquartered in San Diego, as a wholly-owned subsidiary under the leadership of Organovo, Inc.'s current management team, headed by Chief Executive Officer Keith Murphy. The shares of common stock of the merged company have been quoted on the OTC markets and on the OTCQB under the symbol "ONVO" since February 14, 2012.

The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be resold absent registration under or exemption from such Act. T
'/>"/>

SOURCE Organovo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Organovo, Inc. Investor Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
2. Organovo, Inc. to Webcast, Live, at RetailInvestorConferences.com on March 1st
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Organovo Appoints Robert Baltera to Board
5. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
6. Floridas Leading Fertility Center Announces Successful Baby Delivery via Egg Freezing
7. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
8. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
9. Proteonomix Announces a Private Placement of $3.8 Million
10. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
11. ARUP Laboratories Announces Creation of Business Innovations Division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE ... financial results will be released on Thursday, August 13, ... Eastern Time, Pfenex management will host a conference call ... update.  A press release outlining the financial results and ... call. Please call 1-866-376-8058 (US) or 1-412-542-4131 ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact ... products , in particular, drug/device combinations. The current system received a score of 0 ... for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris ... announced it has selected an optimized Erk inhibitor ... in the development of a new class of ... pathway represents a prime target for therapeutic intervention ... activities and survival benefits for B-Raf and Mek ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized ... The core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical ...
Breaking Biology Technology:Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3
... sets the new global standard to eradicate ... in health care facilities, including MRSA and ... ... BioNeutral announces successful,testing of its Ygiene(TM) Hospital Grade antimicrobial against,antibiotic-resistant microorganisms ...
... Xceed Molecular, a pioneer in,the development of ... has selected the company,s Ziplex,System as a recipient ... Oscars of Invention by The Chicago Tribune, the ... mark of excellence known to industry,government, and academia ...
... SEATTLE and OSLO, Norway, Aug. 19 ... Affitech AS, a,Norwegian human antibody therapeutics company, ... agreement for the discovery and development of ... or mannan-binding,lectin-associated serine protease-2, mediates activation of ...
Cached Biology Technology:BioNeutral's Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World 2BioNeutral's Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World 3BioNeutral's Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World 4Xceed Ziplex(R) System for Automated Gene-Expression Analysis Wins 2008 R&D 100 Award 2Affitech and Omeros Enter Into Antibody Discovery and Development Agreement 2Affitech and Omeros Enter Into Antibody Discovery and Development Agreement 3
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... detected from space for the first time using optical ... aboard Envisat. The ability to monitor Sargassum globally will ... the ocean and better predict climate change. Credit: ESA ... ships in its dense floating vegetation, has been detected ...
... are moving closer to understanding why the most lethal ... treatment in the past three decades. They have been ... a protozoan gene that contributes to such resistance. And ... constructed over a two-year period is believed to be ...
... postdoctoral fellow at the University of Oregon, has shown that ... soil bacteria needed to provide a natural fertilizer to crops. ... boost crop yields may instead be contributing to growth problems, ... years of research both in the test tube and, now, ...
Cached Biology News:Envisat captures first image of Sargassum from space 2Largest synthetic gene ever built offers insights into anti-malarial drug resistance 2Largest synthetic gene ever built offers insights into anti-malarial drug resistance 3Largest synthetic gene ever built offers insights into anti-malarial drug resistance 4Pesticides choke pathway for nature to produce nitrogen for crops 2Pesticides choke pathway for nature to produce nitrogen for crops 3
... does for enzyme-/substrate-based blotting what intensifying screens do ... up to 10-fold (or one order of magnitude) ... Signal Enhancer membrane treatment is a simple, 15-minute ... current Western blotting protocol. The result is an ...
...
... Expression is a revolutionary new ... analysis. Utilising a novel interface, Expression ... information incredibly simple. Expression uses the ... new standards in the way sequences ...
... Solution is a comprehensive suite of ... specifically designed to reliably extract biological ... genomic studies containing thousands of samples, ... efficient and will analyze large data ...
Biology Products: